Grit Biotherapeutics

Grit Biotherapeutics is a clinical-stage biotechnology company dedicated to developing next-generation Tumor-Infiltrating Lymphocyte (TIL) therapies for the treatment of solid tumors. Headquartered in Shanghai, the company leverages its proprietary platforms, including StaViral and Stem-T, to enhance the expansion, persistence, and potency of TILs. Their lead candidate, GT101, was the first TIL therapy to receive IND approval in China and is currently undergoing clinical evaluation for multiple advanced solid tumor indications. Grit Bio's pipeline also includes genetically modified TIL programs designed to overcome the immunosuppressive tumor microenvironment. By integrating advanced gene engineering with cell therapy, the company aims to provide curative options for cancer patients globally.